Review



cell culture human nsclc cell lines  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC cell culture human nsclc cell lines
    Cell Culture Human Nsclc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 8975 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell culture human nsclc cell lines/product/ATCC
    Average 99 stars, based on 8975 article reviews
    cell culture human nsclc cell lines - by Bioz Stars, 2026-03
    99/100 stars

    Images



    Similar Products

    cell culture human nsclc cell lines  (ATCC)
    99
    ATCC cell culture human nsclc cell lines
    Cell Culture Human Nsclc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cell culture human nsclc cell lines/product/ATCC
    Average 99 stars, based on 1 article reviews
    cell culture human nsclc cell lines - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    human nsclc cell lines h1299  (ATCC)
    96
    ATCC human nsclc cell lines h1299
    Human Nsclc Cell Lines H1299, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human nsclc cell lines h1299/product/ATCC
    Average 96 stars, based on 1 article reviews
    human nsclc cell lines h1299 - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    human non small cell lung carcinoma nsclc cell lines  (ATCC)
    99
    ATCC human non small cell lung carcinoma nsclc cell lines
    (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all <t>NSCLC</t> PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.
    Human Non Small Cell Lung Carcinoma Nsclc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human non small cell lung carcinoma nsclc cell lines/product/ATCC
    Average 99 stars, based on 1 article reviews
    human non small cell lung carcinoma nsclc cell lines - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    hypoxia treatment human nsclc cell lines  (ATCC)
    99
    ATCC hypoxia treatment human nsclc cell lines
    (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all <t>NSCLC</t> PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.
    Hypoxia Treatment Human Nsclc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hypoxia treatment human nsclc cell lines/product/ATCC
    Average 99 stars, based on 1 article reviews
    hypoxia treatment human nsclc cell lines - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    human nsclc cancer cell line hcc827  (ATCC)
    99
    ATCC human nsclc cancer cell line hcc827
    (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all <t>NSCLC</t> PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.
    Human Nsclc Cancer Cell Line Hcc827, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human nsclc cancer cell line hcc827/product/ATCC
    Average 99 stars, based on 1 article reviews
    human nsclc cancer cell line hcc827 - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    human nsclc cell a549  (ATCC)
    99
    ATCC human nsclc cell a549
    (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all <t>NSCLC</t> PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.
    Human Nsclc Cell A549, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human nsclc cell a549/product/ATCC
    Average 99 stars, based on 1 article reviews
    human nsclc cell a549 - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    human nsclc cell lines  (ATCC)
    99
    ATCC human nsclc cell lines
    (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all <t>NSCLC</t> PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.
    Human Nsclc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human nsclc cell lines/product/ATCC
    Average 99 stars, based on 1 article reviews
    human nsclc cell lines - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all NSCLC PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.

    Journal: bioRxiv

    Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

    doi: 10.64898/2026.02.17.706284

    Figure Lengend Snippet: (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all NSCLC PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.

    Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

    Techniques: Viability Assay, Flow Cytometry, Clonogenic Assay, Control, Western Blot, Transfection, MANN-WHITNEY

    Journal: bioRxiv

    Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

    doi: 10.64898/2026.02.17.706284

    Figure Lengend Snippet:

    Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

    Techniques: Inhibition, Mutagenesis

    (a, b) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. (a) Left panels: representative immunoblots of the indicated proteins. GAPDH was used as a loading control. Right panels: densitometric quantification (fold change) of SF3B1, ATR or DNA-PKcs signal normalized to GAPDH signal. Mean ± SD. n=3. (b) RT-qPCR (fold change) of SF3B1 , ATR or PRKDC mRNA level. Mean ± SD. n = 3. (a, b) Mann-Whitney t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p<0.0001. (c) Correlation between SF3B1 and DNA-PKcs or ATR protein levels in a series of 77 NSCLC cell lines based on CCLE database. (d) Correlation between SF3B1 and PRKDC mRNA levels in lung adenocarcinoma patients retrieved from TCGA public database.

    Journal: bioRxiv

    Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

    doi: 10.64898/2026.02.17.706284

    Figure Lengend Snippet: (a, b) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. (a) Left panels: representative immunoblots of the indicated proteins. GAPDH was used as a loading control. Right panels: densitometric quantification (fold change) of SF3B1, ATR or DNA-PKcs signal normalized to GAPDH signal. Mean ± SD. n=3. (b) RT-qPCR (fold change) of SF3B1 , ATR or PRKDC mRNA level. Mean ± SD. n = 3. (a, b) Mann-Whitney t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p<0.0001. (c) Correlation between SF3B1 and DNA-PKcs or ATR protein levels in a series of 77 NSCLC cell lines based on CCLE database. (d) Correlation between SF3B1 and PRKDC mRNA levels in lung adenocarcinoma patients retrieved from TCGA public database.

    Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

    Techniques: Transfection, Control, Western Blot, Quantitative RT-PCR, MANN-WHITNEY

    (a) Overall Rate Response (ORR) of all NSCLC PDXs (n = 25) treated with 4 mg/kg cisplatin, 5 mg/kg pladienolide B or a combination of both as compared to vehicle condition. Two-tails Mann-Whitney t test. ** p< 0.01, *** p< 0.001. (b) Probability of tumor progression (Relative Tumor Volume = 2) in control, pladienolide B-, cisplatin- or pladienolide B + cisplatin-treated PDXs. n = 7. Log-rank test. * p< 0.05, ** p < 0.01, *** p< 0.001. (c) LCF26 and ML1LC2 PDXs were treated with vehicle (ctrl), 4 mg/kg cisplatin, 5 mg/kg pladienolide B, or a combination of both. Left panels: immunoblots of DNA-PKCs and ATR. 3 PDXs/condition. GAPDH was used as a loading control. Right panels: normalized expression of DNA-PKcs or ATR according to GAPDH. Mann-Whitney t test. * p< 0.05, ** p< 0.01. (d) RT-PCR analysis of skipping of MLH3 -Ex8 in each PDX (3 distinct mice/PDX). Representative agarose gels of amplified products. Right numbers indicate amplicon size (in base pairs). Below numbers indicated the percentage of exon 8 exclusion. Mean ± SD.

    Journal: bioRxiv

    Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

    doi: 10.64898/2026.02.17.706284

    Figure Lengend Snippet: (a) Overall Rate Response (ORR) of all NSCLC PDXs (n = 25) treated with 4 mg/kg cisplatin, 5 mg/kg pladienolide B or a combination of both as compared to vehicle condition. Two-tails Mann-Whitney t test. ** p< 0.01, *** p< 0.001. (b) Probability of tumor progression (Relative Tumor Volume = 2) in control, pladienolide B-, cisplatin- or pladienolide B + cisplatin-treated PDXs. n = 7. Log-rank test. * p< 0.05, ** p < 0.01, *** p< 0.001. (c) LCF26 and ML1LC2 PDXs were treated with vehicle (ctrl), 4 mg/kg cisplatin, 5 mg/kg pladienolide B, or a combination of both. Left panels: immunoblots of DNA-PKCs and ATR. 3 PDXs/condition. GAPDH was used as a loading control. Right panels: normalized expression of DNA-PKcs or ATR according to GAPDH. Mann-Whitney t test. * p< 0.05, ** p< 0.01. (d) RT-PCR analysis of skipping of MLH3 -Ex8 in each PDX (3 distinct mice/PDX). Representative agarose gels of amplified products. Right numbers indicate amplicon size (in base pairs). Below numbers indicated the percentage of exon 8 exclusion. Mean ± SD.

    Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

    Techniques: MANN-WHITNEY, Control, Western Blot, Expressing, Reverse Transcription Polymerase Chain Reaction, Amplification